Fintel reports that on October 2, 2023, Cantor Fitzgerald reiterated coverage of Pfizer (NYSE:PFE) with a Overweight recommendation.
Analyst Price Forecast Suggests 32.47% Upside
As of August 31, 2023, the average one-year price target for Pfizer is 44.97. The forecasts range from a low of 32.32 to a high of $78.75. The average price target represents an increase of 32.47% from its latest reported closing price of 33.95.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Pfizer is 79,124MM, an increase of 1.52%. The projected annual non-GAAP EPS is 5.02.
What is the Fund Sentiment?
There are 4301 funds or institutions reporting positions in Pfizer. This is a decrease of 190 owner(s) or 4.23% in the last quarter. Average portfolio weight of all funds dedicated to PFE is 0.57%, a decrease of 12.20%. Total shares owned by institutions decreased in the last three months by 1.15% to 4,373,898K shares. 
The put/call ratio of PFE is 0.81, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 233,110K shares representing 4.13% ownership of the company. In it's prior filing, the firm reported owning 218,932K shares, representing an increase of 6.08%. The firm decreased its portfolio allocation in PFE by 8.65% over the last quarter.
Capital World Investors holds 199,013K shares representing 3.52% ownership of the company. In it's prior filing, the firm reported owning 231,512K shares, representing a decrease of 16.33%. The firm decreased its portfolio allocation in PFE by 28.09% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 176,053K shares representing 3.12% ownership of the company. In it's prior filing, the firm reported owning 173,954K shares, representing an increase of 1.19%. The firm decreased its portfolio allocation in PFE by 16.05% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 134,410K shares representing 2.38% ownership of the company. In it's prior filing, the firm reported owning 130,981K shares, representing an increase of 2.55%. The firm decreased its portfolio allocation in PFE by 16.44% over the last quarter.
Geode Capital Management holds 112,873K shares representing 2.00% ownership of the company. In it's prior filing, the firm reported owning 109,853K shares, representing an increase of 2.68%. The firm decreased its portfolio allocation in PFE by 16.45% over the last quarter.
Pfizer Background Information
(This description is provided by the company.)
Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. It strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as one of the world's premier innovative biopharmaceutical companies, it collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, it has worked to make a difference for all who rely on it. It routinely posts information that may be important to investors on its website at www.Pfizer.com.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
